The FDA is proposing the removal of phenylephrine, a popular nasal decongestant, in oral form from over-the-counter use. Here ...
We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a ...
Merck (NYSE: MRK) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.
Merck KGaA is shaping up to take on Daiichi Sankyo and Ono Pharma in the market for tenosynovial giant cell tumour (TGCT) ...
Summit Therapeutics may have a powerful new cancer therapy on its hands. Merck is milking its cash cow oncology drug and ...
Merck KGaA’s $70 million bet on a treatment for a rare, locally aggressive cancer has delivered a phase 3 win. The ...
Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment ...
German sci-tech giant Merck is very optimistic about its prospects in the Chinese market and will continue to strengthen its ...
Ginkgo Bioworks (DNA) completed the first milestone of a partnership with Merck (MRK) focused on improving biologic manufacturing. As part of ...
The Motley Fool on MSN11d
Is Merck Stock a Buy?
Its top-selling treatment, Keytruda, will lose patent protection in a few years. Then Merck will face biosimilar competition ...
The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...